Remove 2022 Remove Pharma Remove Pharmacology
article thumbnail

Mastering Pharmacology: A Game-Changer for Pharma Sales Reps Communicating with HCPs

Pharmaceutical Representative Training

Pharmacology is one of the most fundamental aspects of medication therapy. 1] How can mastering pharmacology give sales reps a competitive advantage when meeting with prospective HCPs? Due to limited knowledge of pharmacology, the sales rep failed to properly communicate and was unable to address the physicians concerns.

article thumbnail

Top-10 ways for Pharma to leverage AI according to…AI

Impetus Digital

In 2022, the AI-fuelled pipeline reportedly expanded at an annual rate of almost 40%. Supply Chain Management Due to geopolitical and climate-related challenges , Pharma supply chain disruptions are becoming increasingly common and complex. Looking back at 2023 , AI for drug discovery saw both wins and losses.

Pharma 92
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Tackling the complex development landscape of pain medicines

European Pharmaceutical Review

There is a clear trend away from developing pharmacological therapies targeting opioid receptors” There is a clear trend away from developing pharmacological therapies targeting opioid receptors. Towards the end of 2023, one sensed an emerging interest from Big Pharma in neuroscience. References Cruccu G, Truini A.

Medicine 102
article thumbnail

Tapping into digital therapeutics to improve neurological outcomes

Pharmaceutical Technology

Companies are testing the use of digital platforms along with pharmacological treatments. But while appealing, the prospects of developing a merged approach that combines both digital and pharmacological therapeutics remain challenging. Securing reimbursement for digital therapeutics also continues to impede its uptake.

article thumbnail

Market outlook to 2032: future trends across the seven major markets

European Pharmaceutical Review

billion in 2022 to $4.1 percent between 2022 and 2032. percent between 2022 and 2032. GlobalData anticipated it will launch in the US and 5EU (France, Germany, Italy, Spain, and the UK) markets during the forecast period, Sulayman Patel, MSci, Pharma Analyst at GlobalData noted. “As percent from $3.2 billion in 2032.

article thumbnail

Astellas loses bid to block Lexiscan generics in US

pharmaphorum

It looks like Astellas has been unsuccessful in its attempt to block Pfizer’s generic medicines unit Hospira from launching a copycat version of big-selling pharmacologic stress agent Lexiscan in the US. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier this year.

article thumbnail

Astellas facing generics to big-selling Lexiscan product in US

pharmaphorum

Astellas has won a reprieve in its attempt to stop Pfizer’s generic medicines unit Hospira launching a copycat version of its pharmacologic stress agent Lexiscan in the US – but only for a couple of weeks. AmphaStar and Glenmark Pharma also claimed FDA approval for versions of the drug earlier this year.